Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data

This 2010 *JCEM* paper pools the two pivotal phase 3 tesamorelin trials in HIV-associated lipodystrophy plus a 26-week safety extension and is the extended-duration counterpart to Falutz et al. NEJM 2007. The two trials together randomized 806 ART-treated HIV patients with excess abdominal fat in a 2:1 ratio to tesamorelin 2 mg daily or placebo for an initial 26-week randomized phase, followed by re-randomization into a 26-week extension. The pooled results confirm and extend the NEJM findings: tesamorelin reduced visceral adipose tissue (VAT), maintained that reduction across the full 52-week period, preserved subcutaneous abdominal fat (the trial's design successfully avoided peripheral lipoatrophy), reduced triglycerides and waist circumference, improved patient-reported body image, and did not produce clinically meaningful changes in glycemic measures over the extended period. Adverse events were predominantly mild injection-site reactions and arthralgia. The 52-week extension data is the basis for the FDA's confidence in chronic dosing being safe within the indicated population — extending from the 26-week pivotal to a year of dosing is what made the chronic-therapy framing supportable. The paper is one of the cleanest examples in the corpus of how a pivotal NEJM trial maps to the broader regulatory dataset that supports an indication.

The pooled analysis combines two trials with somewhat different designs; the safety-extension data is from the subset of patients who continued past week 26 rather than from the full randomized cohort. Generalizability remains limited to the HIV-associated lipodystrophy population the trials enrolled — the data does not extend to non-HIV body-recomposition use, where most off-label biohacker interest sits. Visceral-fat reduction reverses on discontinuation; the chronic-therapy implication is the same as for the GLP-1 class. Industry sponsorship by Theratechnologies is disclosed; the primary endpoints are regulatory-grade and consistent with the FDA review. Readers should treat this paper as the extended-duration confirmation of the 2007 NEJM pivotal rather than as independent evidence — the patient populations overlap by design.